VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, Feb. 1, 2022 /PRNewswire/ Cytiva, a global life sciences leader, announces the winner of its first BioChallenge for the.
VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the.
World Outlook for the Exosome Market: Surging Number of Scientific Papers Investigating Exosomes and their Applications prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
ResearchAndMarkets.com’s offering.
Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
The cargo contained within exosomes can offer prognostic information for a range of diseases – including cardiovascular, renal, neurodegenerative, and metabolic diseases – as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosome